161 results about "Pharmaceutical Dose Form" patented technology

The present invention provides a pharmaceutical composition for use in a dosage form for oral administration to a patient. The composition expands upon contact with gastric fluid and promotes retention of the dosage form in the patient's stomach for a prolonged period of time. The present invention further provides pharmaceutical dosage forms containing an active ingredient, and the pharmaceutical composition. The forms are adapted for immediate or controlled release of the active ingredient. The dosage forms may be used advantageously in the treatment of Parkinson's disease with levodopa and hyperactivity and attention deficit disorder with methylphenidate.

A compressed core for a pharmaceutical dosage form comprising a mixture of (a) at least one pharmaceutically acceptable organic acid, and (b) at least one pharmaceutically acceptable excipient is described. Such compressed core is useful for the preparation of pharmaceutical compositions containing a drug in which dissolution of the drug is favored in acidic environments. Also described are pharmaceutical compositions comprising such compressed core.

The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

A solid pharmaceutical dosage form having a plurality of adhesively-joined subunits and also having one or more of the following: A. (i) a first inert tablet subunit and (ii) a second active subunit; B. (i) a first tablet subunit with a pharmacologically inactive layer in which said layer has a mass of at least 20 mg and (ii) a second subunit; C. a tablet subunit that is provided with a separation mark; or D. (i) a first tablet subunit and (ii) a second capsule subunit that is adhesively joined to said first tablet subunit.

A pH responsive and mucoadhesive pharmaceutical dosage form for the release of a pharmaceutically active agent is described. The dosage form includes a mucoadhesive layer for site-specific mucoadhesion, a water-insoluble outer layer, and an intermediate layer including one or more pharmaceutically active agents for site-specific delivery. The different membranous layers perform different functions in order to create a drug delivery system which is able to deliver a drug to a specific site, for a particular period of time and with a specific drug release pattern. The dosage form can have two or more intermediate layers, each layer comprising an active agent. The mucoadhesive layer can also include an active agents. The dosage form is preferably an oral or buccal delivery form for release of the active agent into the gastro intestinal tract. The intermediate layer can be an electrospun fibrous membrane layer containing the active agent.

The present invention relates to a pharmaceutical dosage form, and methods and system for making the pharmaceutical dosage form. The pharmaceutical dosage form contains a first component and a second component sealed in a container, such as a packet or sachet, blister pack, and capsule. Machines and methods for making the pharmaceutical dosage form is also provided.

The invention provides a tissue engineering scaffold with multi-growth-factor sequential release characteristic, and belongs to the technical field of dosage form variation and preparation method. In the tissue engineering scaffold, together with the characteristics of microspheres sustained release system and scaffold, PLLA/PEG (poly-lactic acid/polyethylene glycol) sustained release microspheres of growth factors such as BMP-2 (bone morphogenetic protein), VEGF (vascular endothelial growth factor), bFGF (basic fibroblast growth factor) are prepared respectively by the multiple emulsion method, so as to construct the tissue engineering scaffold with multi-growth-factor sequential release characteristic. The method is high in drug activity maintaining degree, low in organic solvent residue and easy to operate. The prepared microspheres are narrow in particle size distribution and have an excellent sustained release effect. The pore size distribution of the composite scaffold is 150-300mu m, the connectivity is excellent, the porosity is 76.84%, the compressive strength is 5.11MPa, and the accumulative release amount of 21 days is 60.6%. The scaffold prepared according to the invention has an application prospect in tissue engineering restoration.

The present invention provides a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule; the fill material comprises (a) a selective COX-2 inhibitory drug of low water solubility, and (b) a sulfite compound in an amount sufficient to inhibit cross-linking of gelatin in said gelatin capsule upon storage of the dosage form in a closed container maintained at 40° C. and 75% relative humidity for a period of 6 months.

The invention belongs to the technical field of pharmacy, and specifically relates to a posaconazole solid dispersion and a preparation method thereof. The invention discloses a posaconazole solid dispersion which is composed of posaconazole and a water-soluble polymer according to a weight ratio of 1:0.5-10, and a pharmaceutical composition comprising the same. The provided posaconazole solid dispersion can prominently improve the dissolution rate of antifungal agent posaconazole, which is hard to dissolve, in small intestines, and is capable of prominently increasing the biological utilization rate of posaconazole. The pharmaceutical dosage forms prepared from the pharmaceutical composition comprising the provided solid dispersion has the advantages of simple preparation technology and stable quality.

At present, the most prevalent pharmaceutical dosage forms, the oral immediate-release tablets and capsules, are granular solids. The problem of such solids is that their microstructure and properties are not predictable from physical models. As a consequence, product development and manufacture are resource-intensive and time-consuming, and quality control is statistical by testing instead of by design. Furthermore, the range of the drug release rate, and the variety of active ingredients that can be processed to a functional product, are limited in such dosage forms. Presented herein, accordingly, is a fibrous dosage form suitable for immediate-release applications prepared by a predictable liquid-based process. The fibrous dosage form includes a drug-containing solid comprising a three dimensional structural network of one or more drug-containing fibers.